LATEST NEWS
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Aprea Therapeutics, Inc. (NASDAQ : APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality.
Cancer treatment is at a turning point—and Aprea Therapeutics is at the forefront of this revolution. Investors are starting to notice the massive potential behind this under-the-radar biotech innovator and their game-changing approach to cancer.
The market for cutting-edge oncology treatments is growing, and Aprea Therapeutics is uniquely positioned with its game-changing focus on synthetic lethality therapy.
IDENTIFYING THE OPPORTUNITY
A HIGHER SUPPORT LEVEL HAS SOLIDIFIED
With a float of less than 5M and few restricted shares, a little bit of investor interest could send this soaring!
KEY LEVELS
Key Level #1: $4.34 (+33.54%)
Key Level #2: $4.99 (+53.54%)
Key Level #3: $6.83 (+110.15%)
Key Level #4: $7.74 (+138.15%)
Potential Support: $2.73
Aprea Therapeutics
(NASDAQ: APRE)
A Commitment to Give Cancer Patients a Choice
Between Aprea Therapeutics novel macrocyclic ATR inhibitor, ATRN-119, and their next-generation inhibitor of the WEE1 kinase, APR-1051, the company has a long pipeline of treatment options in development to give cancer patients a choice in treatment.
WEE1 is a protein kinase that inhibits premature cell cycle progression. Specifically, WEE1 prevents the premature entry of cells into both the DNA synthetic phase of the cell cycle and the phase in which cells divide after the DNA is duplicated. Through these roles, WEE1 prevents loss of genome stability, particularly in CCNE1-overexpressing cancer cells.
APR-1051 is an orally bioavailable, highly potent, and selective small molecule inhibitor of WEE1. APR-1051 has demonstrated in vivo anti-proliferative activity in multiple cancer cell lines. Importantly, the pharmacodynamic properties of APR-1051 include lower off-target inhibition of three members of the PLK family of kinases (PLK1, PLK2, and PLK3), which may improve its therapeutic value.
ATR Program: ATRN-119
The ataxia telangiectasia and Rad3-related (ATR) kinase is a master regulator of the DNA damage response, with key roles in cell cycle control and DNA repair following replication stress. Aprea Therapeutics has developed ATRN-119, the first macrocyclic ATR inhibitor to enter clinical trials (NCT04905914).
Meet the Team Behind Aprea Therapeutics (NASDAQ: APRE)
Oren Gilad, Ph. D - Prident and CEO
Oren Gilad, Ph.D., has served as Chief Executive Officer of Aprea Therapeutics since July 2022 and as President and a member of its Board of Directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics. Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities. Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR pathway in cancer development and treatment. Dr. Gilad earned his doctorate from the University of California at Davis and his B.S. from the Hebrew University, Jerusalem, Israel.
John P. Hamill, CPA - Senior Vice President and CFO
John joined Aprea in January 2023 from Windtree Therapeutics where he served as Senior Vice President and Chief Financial Officer since 2020. He brings more than 30 years of financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. He brings broad-based experience in financial, administrative, information technology, and facility functions, in addition to successfully completing IPO and follow-on offerings for several pharmaceutical companies. John has also recently provided consulting services to various life science companies, headed up finance at Trevena, Inc., where he was instrumental in successfully raising equity; NephroGenex, Inc., where he actively led the IPO and subsequent financial restructuring and sale of the company; Savient Pharmaceuticals, where he led a sale process resulting in $120 million in proceeds; and PharmaNet where he successfully completed its sale for approximately $250 million, which then became known as PharmaNet Development Group, where he directed financial and administrative operations for the company. John received a B.S. in Accounting and Business and Computer Science from DeSales University and is a certified public accountant.
Sources
- Source 1: https://finance.yahoo.com/quote/APRE/
- Source 2: https://ir.aprea.com/stock-information/stock-quote-chart
- Source 3: https://aprea.com/management-team/
- Source 4: https://aprea.com/
- Source 5: https://aprea.com/aprea-therapeutics-pipeline/
- Source 6: https://ir.aprea.com/news-and-events/press-releases
- Source 7: https://ir.aprea.com/investor-resources/investor-faqs
- Source 8: https://aprea.com/aprea-therapeutics-clinical-trials/
- Source 9: https://aprea.com/about/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to an agreement between Virtus Media LLC and JRZ Capital LLC, Virtus Media LLC has been hired by JRZ Capital LLC for a period beginning on 2024-12-04 and ending 2024-12-27 to publicly disseminate information about NASDAQ:APRE via digital communications. We have been paid forty five thousand dollars USD. Virtus Media Group LLC has agreed to pay social media influencer #1 five thousand dollars USD and social media influencer #2 eight hundred dollars USD and social media influencer #3 two hundred dollars USD and social media influencer #4 one hundred fifty dollars USD and social media influencer #5 two hundred dollars USD and social media influencer #6 two hundred fifty dollars USD and social media influencer #7 four hundred dollars USD and social media influencer #8 one thousand five hundred dollars USD and social media influencer #9 three thousand five hundred dollars USD and social media influencer #10 one thousand five hundred dollars USD and social media influencer #11 one thousand dollars USD.
© Virtus Media 2024
